2021 年 12 巻 2 号 p. 69-75
Purpose: Bevacizumab and gemcitabine are key drugs for treating platinum-resistant recurrent ovarian cancer (PROC) patients. We retrospectively investigated its efficacy and safety of the combination chemotherapy in PROC patients.
Methods: Twenty-one patients who were diagnosed with PROC at our hospital that had received a course of multidrug therapy with gemcitabine and bevacizumab between March 2016–March 2018 were analyzed. Therapeutic effects were evaluated in accordance with the RECIST guidelines (version 1.1).
Results: Five patients had a complete response (CR), 5 had a partial response (PR), 8 had stable disease (SD), and 2 had progressive disease (PD). The response rate (CR + PR) was 50%, and the disease-control rate was 90%. The median progression-free survival (PFS) was 6 months (5–11 months), and the median overall survival (OS) was 11 months (11–23 months). Grade 3/4 hematological toxicities included neutropenia (Grade 3: 4 patients and Grade 4: 4 patients), anemia (Grade 3: 4 patients and Grade 4: 1 patient) and thrombocytopenia (Grade 3: 2 patients). No febrile neutropenia occurred. Grade 3 non-hematological toxicities included thromboembolism (2 patients), hypertension (2 patients), and interstitial pneumonia (1 patient). No Grade ≥3 proteinuria or digestive tract perforation occurred.
Conclusions: The combination chemotherapy with gemcitabine and bevacizumab was feasible, effective and safe in PROC patients.
